Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Collegium Pharmaceutical (COLL) EPS (Weighted Average and Diluted) (2019 - 2026)

Collegium Pharmaceutical has reported EPS (Weighted Average and Diluted) over the past 8 years, most recently at $0.46 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) rose 27.78% year-over-year to $0.46; the TTM value through Dec 2025 reached $1.71, down 8.06%, while the annual FY2025 figure was $1.73, 6.99% down from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was $0.46 at Collegium Pharmaceutical, down from $0.84 in the prior quarter.
  • Over five years, EPS (Weighted Average and Diluted) peaked at $1.79 in Q2 2021 and troughed at -$0.73 in Q4 2021.
  • A 5-year average of $0.29 and a median of $0.34 in 2023 define the central range for EPS (Weighted Average and Diluted).
  • Biggest five-year swings in EPS (Weighted Average and Diluted): tumbled 465.0% in 2021 and later surged 5200.0% in 2023.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$0.73 in 2021, then skyrocketed by 71.23% to -$0.21 in 2022, then surged by 490.48% to $0.82 in 2023, then tumbled by 56.1% to $0.36 in 2024, then rose by 27.78% to $0.46 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for COLL at $0.46 in Q4 2025, $0.84 in Q3 2025, and $0.34 in Q2 2025.